转化生物医学

  • 国际标准期刊号: 2172-0479
  • 期刊 h 指数: 16
  • 期刊引用分数: 5.91
  • 期刊影响因子: 3.66
索引于
  • 打开 J 门
  • Genamics 期刊搜索
  • 期刊目录
  • 研究圣经
  • 全球影响因子 (GIF)
  • 中国知网(CNKI)
  • 引用因子
  • 西马戈
  • 电子期刊图书馆
  • 研究期刊索引目录 (DRJI)
  • OCLC-WorldCat
  • 普罗奎斯特传票
  • 普布隆斯
  • 米亚尔
  • 大学教育资助委员会
  • 日内瓦医学教育与研究基金会
  • 谷歌学术
  • 夏尔巴罗密欧
  • 秘密搜索引擎实验室
  • 研究之门
分享此页面

抽象的

Bone Marrow-derived Mononuclear Stem Cell Implantation in Patients with Buerger's Disease

Shapour Shahgasempour , Habibullah Peirovi , Afshin Fathi

Background: Patients suffering from Thromboangiitis obliterans (TAO) have endothelial cell dysfunction and the severity of the disease lies in the need for amputation in more than a quarter of all sufferers.

Methods and Findings: We report the safety and feasibility of autologous implantation of circulating mononuclear cells for patients suffering from Buerger’s disease following bone-marrow mobilization with granulocyte colony stimulating factor (5 mg/kg/day for 5-7 days). Six patients participated in this study. Mononuclear cells were separated by Cobas Spectra cell separator. MNCs, CD34+ and CD133+ cells were enumerated prior to intramuscular injection into the affected foot/ limb muscles at multiple sites on the collection day. Stem cell injection prevented disease progression in all six patients. In this small cohort of patients with critical limb ischemia, quality of life improved significantly over a two year period. Also, pain-free walking distance in all patients showed significant improvement.

Conclusions: Autologous mononuclear cell containing CD34+/CD133+ stem cells collected from peripheral blood following G-CSF mobilization is effective, safe and results in sustained clinical results for patients with severe peripheral occlusive arterial disease.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证